VERU Veru Inc
- 0.625
- 0.000-0.05%
Veru Inc News
Following the US Secretary of Health, Trump's nomination for the FDA Commissioner seems to be another anti-vaccine advocate.
Makari is a surgeon who opposes overtreatment, advocates for re-evaluating hormone replacement therapy, and reducing the overuse of antibiotics.
US pharmaceutical stocks plummet, has the market overreacted to Little Kennedy?
Source: Analysis from Wall Street News states that even if Kennedy is confirmed as the Secretary of Health in the usa, he may not be able to "make a big impact". First, there may be divisions within Trump's team; secondly, it is uncertain whether Kennedy has the authority to appoint leaders of departments like the FDA; finally, Trump may appoint individuals with industry backgrounds as FDA commissioners, directing Kennedy's attention to focus on nutrition rather than pharmaceutical approvals. The famous "anti-vaccine pioneer" and advocate for healthy eating, the new government-nominated Secretary of Health Robert Kennedy, is dining with the loyal "fast food enthusiast" Trump, who promotes rapid vaccine development.
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
Vaccines stocks in the usa collectively plummet! Trump surprisingly appoints an anti-vaccine advocate as the Secretary of Health in the usa.
① Trump nominated Robert F. Kennedy Jr. as the new Secretary of Health and Human Services, which triggered a sell-off in vaccine companies; ② Kennedy advocates very radical views, opposing vaccines since 2005, and questioning the transparency of the usa government in public health information.
Some Veru Inc. (NASDAQ:VERU) Shareholders Look For Exit As Shares Take 34% Pounding
Oppenheimer Maintains Veru Inc(VERU.US) With Buy Rating, Maintains Target Price $5
Express News | Veru Inc - Topline Results From Phase 2B Quality Trial Expected in January 2025
Express News | Veru Inc - Enobosarm Generally Well-Tolerated With No Increase in Gastrointestinal Side Effects
Veru To Present Meta-Analysis of 4 Previous Randomized Clinical Trials That Support Potential Of Enobosarm To Optimize Weight Loss At ObestiyWeek
"Weight-loss miracle drug" causing muscle loss, biotechnology companies like Regeneron Pharmaceuticals (REGN.US) are developing new treatments.
Wegovy and Zepbound, along with other GLP-1 class drugs, have significant effects on weight loss, but this weight loss largely reduces muscle mass.
Weight Loss Drugs Have One Big Issue; These Companies Want to Fix It
12 Consumer Staples Stocks Moving In Thursday's After-Market Session
Veru Inc (VERU) Q3 2024 Earnings Call Highlights: Strategic Cost Management and Revenue Growth ...
Express News | Veru Inc: On Aug 19, Delivered Notice to Jefferies LLC to Terminate Open Market Sales Agreement
Earnings Beat: Veru Inc. (NASDAQ:VERU) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Veru Inc | 10-Q: Q3 2024 Earnings Report
Express News | Veru Inc - Qtrly Net Loss per Basic and Diluted Common Shares Outstanding $0.07
Veru GAAP EPS of -$0.07, Revenue of $4M
Veru 3Q Research and Development Expenses $4.9M >VERU
Veru 3Q Rev $4.0M >VERU
Analysis
Price Target
No Data
No Data
